Company: RPTX
Filing Date: 2025-03-31
Form Type: 8-K
Source: 0001193125-25-068880
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-31
Form: 8-K
Item: Item 5.02
Chunk 1
---
 during the12-monthperiod following the Effective Date; and (vi) the accelerated vesting of all unvested option awards and restricted stock unit awards that are subject to a time-based vesting schedule held by Mr. Segal as if Mr. Segal had remained employed for an additional 15 months following the Effective Date.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2025.